Curi RMB Capital LLC Trims Stake in Catalent, Inc. (NYSE:CTLT)

Curi RMB Capital LLC reduced its stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 23.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 96,590 shares of the company's stock after selling 29,662 shares during the quarter. Curi RMB Capital LLC owned about 0.05% of Catalent worth $5,850,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its position in Catalent by 14.9% in the 1st quarter. Russell Investments Group Ltd. now owns 27,636 shares of the company's stock valued at $1,560,000 after acquiring an additional 3,578 shares in the last quarter. ProShare Advisors LLC boosted its position in Catalent by 15.3% during the first quarter. ProShare Advisors LLC now owns 28,763 shares of the company's stock valued at $1,624,000 after purchasing an additional 3,814 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Catalent by 27.9% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 218,586 shares of the company's stock valued at $12,339,000 after purchasing an additional 47,739 shares in the last quarter. Blair William & Co. IL raised its stake in shares of Catalent by 3.0% during the 1st quarter. Blair William & Co. IL now owns 41,998 shares of the company's stock worth $2,371,000 after purchasing an additional 1,220 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Catalent by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company's stock valued at $1,151,872,000 after buying an additional 218,682 shares during the last quarter.

Catalent Price Performance

Catalent stock traded up $0.19 during midday trading on Friday, reaching $59.10. The company's stock had a trading volume of 1,486,410 shares, compared to its average volume of 2,034,855. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The stock has a market cap of $10.73 billion, a PE ratio of -26.15, a price-to-earnings-growth ratio of 2.35 and a beta of 1.16. Catalent, Inc. has a 52 week low of $36.74 and a 52 week high of $61.20. The business has a 50-day moving average price of $59.84 and a 200-day moving average price of $58.18.

Catalent (NYSE:CTLT - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent's quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.10) EPS. On average, sell-side analysts predict that Catalent, Inc. will post 0.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on CTLT shares. Robert W. Baird reissued a "neutral" rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Baird R W lowered Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. William Blair reaffirmed a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, StockNews.com upgraded shares of Catalent from a "sell" rating to a "hold" rating in a report on Thursday. Nine research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Catalent presently has a consensus rating of "Hold" and a consensus price target of $59.83.

Insider Transactions at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 over the last ninety days. 0.31% of the stock is currently owned by insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.